- GlobeNewswire•2 days agoVical Announces Initiation of a Phase 2 Trial of Its HSV-2 Therapeutic DNA Vaccine for Genital Herpes
SAN DIEGO, Sept. 26, 2016-- Vical Incorporated announced today the initiation of a Phase 2 trial of the company’ s Vaxfectin™- formulated, bivalent, therapeutic DNA vaccine for herpes simplex virus type ...
- Zacks•8 days ago
Vical (VICL) and Astellas reported disappointing top-line phase II data on cytomegalovirus vaccine candidate, ASP0113, in kidney transplant patients.
- Insider Monkey•9 days agoSarepta Therapeutics Inc (SRPT), PTC Therapeutics, Inc. (PTCT) and More: Here’s Why These Stocks Are on Investors’ Radars Today
Wall Street is in bull mode today as all three major indexes are in the green, with the Dow rising 90 points, the S&P 500 increasing 0.5% and the NASDAQ inching up 0.4%. In addition crude futures have surged over 2% as investors look forward to the informal OPEC/Russia meeting later this month. Among the stocks that have […]
Vical Incorporated (VICL)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
|Bid||3.05 x 1000|
|Day's Range||3.11 - 3.22|
|52wk Range||2.80 - 5.40|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-4.53|
|Avg Vol (3m)||35,073|
|Dividend & Yield||N/A (N/A)|